Ernexa Therapeutics Inc. (ERNA) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysten schätzen Gewinn pro Aktie (EPS) von $-153.00 und Umsatz von $0.00B für das nächste Geschäftsjahr.
Gewinn pro Aktie (EPS) Erfolgsbilanz: 2024: tatsächlich $-3.26 vs Schätzung $-153.00 (übertroffen +97.9%). 2025: tatsächlich $-2.24 vs Schätzung $-162.00 (übertroffen +98.6%). Analysten-Genauigkeit: 0%.
GpA-Schätzungen — ERNA
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$3.26
vs Est –$153.00
▲ 4,593.3% off
2025
Actual –$2.24
vs Est –$162.00
▲ 7,132.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Umsatzschätzungen — ERNA
100%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▼ 0.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
